Abstract
Objective
To compare the efficacy and safety of standard doses of Caffeine and Aminophylline for Apnea of prematurity.
Study design
Randomized controlled trial.
Setting
Tertiary-care referral centre and a teaching institution in Southern India. Trial was conducted from February 2012 to January 2015.
Participants
240 preterm (≤34 wk) neonates with apnea of prematurity.
Interventions
Neonates randomized into two groups: Caffeine group received loading dose of caffeine citrate (20 mg/kg) followed by 5 mg/kg/day maintenance dose every 24 hour. Aminophylline group received loading dose of Aminophylline–5 mg/kg and maintenance dose of 1.5 mg/kg 8-hourly.
Outcome measures
Difference in apneic spells, associated respiratory morbidity, and acute adverse events were assessed. Association of efficacy with therapeutic drug levels was also evaluated.
Results
Infants on aminophylline experienced less apnea spells in 4-7 days of therapy (P=0.03). Mean apnea rate and isolated desaturations were similar in 1-3, 4-7 and 8-14 days of therapy. No difference was noted in duration of Neonatal Intensive Care Unit stay and hospital stay. Mean heart rate was significantly high in Aminophylline group (P<0.001). Risk of develo** tachycardia was less (RR 0.30; 95% CI range 0.15 to 0.60; P<0.001) in Caffeine- over Aminophylline-treated infants.
Conclusion
Aminophylline is as effective as caffeine for prevention of apneic spells in preterm neonates; however, dosage optimization needs to be done to reduce toxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Change history
25 October 2017
In Table II, P value in first row (against ‘continuing apnea’ at 1–3 d of therapy) should be 0.05 in place of 0.03; and in second row (against ‘continuing apnea’ at 4–7 d of therapy), P value should be 0.03 in place of 0.05.
References
Abu-Shaweesh JM, Martin RJ. Neonatal apnea: what’s new? Pediatr Pulmonol. 2008;43:937–44.
Henderson-Smart DJ, De Paoli AG. Methylxanthine treatment for apnoea in preterm infants. Cochrane Database Syst Rev. 2010;12: CD000432.
Chaudhuri M, Garg SK, Narang A, Bhakoo ON. Kinetics of theophylline in apnea of prematurity in small for gestational age babies. Indian Pediatr. 1996;33:181–7.
Larsen PB, Brendstrup L, Skov L, Flachs H. Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates. Acta Paediatr Oslo Nor 1992. 1995;84:360–4.
Brouard C, Moriette G, Murat I, Flouvat B, Pajot N, Walti H, et al. Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. Am J Dis Child 1960. 1985;139:698–700.
Scanlon JE, Chin KC, Morgan ME, Durbin GM, Hale KA, Brown SS. Caffeine or theophylline for neonatal apnoea? Arch Dis Child. 1992;67:425–8.
Hendy H, Wandita S, Kardana IM. Efficacy of aminophylline vs caffeine for preventing apnea of prematurity. Paediatrica Indonesiana. 2014;54:365–71.
Skouroliakou M, Bacopoulou F, Markantonis SL. Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. J Paediatr Child Health. 2009;45:587–92.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article is available at https://doi.org/10.1007/s13312-017-1160-9.
Rights and permissions
About this article
Cite this article
Shivakumar, M., Jayashree, P., Najih, M. et al. Comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity in preterm (≤34 weeks) neonates: A randomized controlled trial. Indian Pediatr 54, 279–283 (2017). https://doi.org/10.1007/s13312-017-1088-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-017-1088-0